A Phase II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab
This study is being done to test the safety of combining Entinostat with Nivolumab and Ipilimumab. It will also measure the percentage of patients whose tumor shrank after receiving Entinostat with Nivolumab and Ipilimumab.
This study will assess the immunomodulatory activity of entinostat in patients who have progressed while receiving the immune-checkpoint inhibitors nivolumab and ipilimumab.
Participants will not be paid for their participation.
- IRB Number: 1803724970 (GU17-326)
- Research Study Identifier: TX8870
- Principal Investigator: Roberto Pili, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required